var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:TAH&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:TAH\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:TAH\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 1. Peer-Reviewed Journal Papers\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n Marom, G.; Chiu, W. C.; Crosby, J. R.; DeCook, K. J.; Prabhakar, S.; Horner, M.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n \n Numerical Model of Full-Cardiac Cycle Hemodynamics in a Total Artificial Heart and the Effect of Its Size on Platelet Activation.\n \n \n \n \n\n\n \n\n\n\n J. Cardiovasc. Transl. Res, 7: 788-796. 2014.\n \n\n\n\n
\n\n\n\n \n \n \"Numerical link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 11 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z21,\r\n author = {Marom, G. and Chiu, W-. C. and Crosby, J. R. and DeCook, K. J. and Prabhakar, S. and Horner, M. and Slepian, M. J. and Bluestein, D.},\r\n year = {2014},\r\n title = {Numerical Model of Full-Cardiac Cycle Hemodynamics in a Total Artificial Heart and the Effect of Its Size on Platelet Activation},\r\n journal = {J. Cardiovasc. Transl. Res},\r\n volume = {7},\r\n issue = {9},\r\n pages = {788-796},\r\n url_Link = {https://doi.org/10.1007/s12265-014-9596-y},\r\n abstract = {The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study's aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.},\r\n project = {TAH},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study's aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.\n
\n\n\n
\n\n\n
\n \n\n \n \n Slepian, M. J.; Alemu, Y.; Girdhar, G.; Soares, J. S.; Smith, R. G.; Einav, S.; and Bluestein, D.\n\n\n \n \n \n \n \n The SynCardia™ total artificial heart: in vivo, in vitro, and computational modeling studies.\n \n \n \n \n\n\n \n\n\n\n J. Biomech, 46: 266-275. Erratum in: 46(7):1414. 2013.\n \n\n\n\n
\n\n\n\n \n \n \"The paper\n  \n \n \n \"The link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 12 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z33,\r\n author = {Slepian, M. J. and Alemu, Y. and Girdhar, G. and Soares, J. S. and Smith, R. G. and Einav, S. and Bluestein, D.},\r\n year = {2013},\r\n title = {The SynCardia™ total artificial heart: in vivo, in vitro, and computational modeling studies},\r\n journal = {J. Biomech},\r\n volume = {46},\r\n issue = {2},\r\n pages = {266-275. Erratum in: 46(7):1414},\r\n url_Paper={/labs/dbluestein/PDF/Slepian_2013_SynCardia_TAH.pdf},\r\n url_Link = {https://doi.org/10.1016/j.jbiomech.2012.11.032},\r\n abstract = {The SynCardia() total artificial heart (TAH) is the only FDA-approved TAH in the world. The SynCardia() TAH is a pneumatically driven, pulsatile system capable of flows of >9L/min. The TAH is indicated for use as a bridge to transplantation (BTT) in patients at imminent risk of death from non-reversible bi-ventricular failure. In the Pivotal US approval trial the TAH achieved a BTT rate of >79%. Recently a multi-center, post-market approval study similarly demonstrated a comparable BTT rate. A major milestone was recently achieved for the TAH, with over 1100 TAHs having been implanted to date, with the bulk of implantation occurring at an ever increasing rate in the past few years. The TAH is most commonly utilized to save the lives of patients dying from end-stage bi-ventricular heart failure associated with ischemic or non-ischemic dilated cardiomyopathy. Beyond progressive chronic heart failure, the TAH has demonstrated great efficacy in supporting patients with acute irreversible heart failure associated with massive acute myocardial infarction. In recent years several diverse clinical scenarios have also proven to be well served by the TAH including severe heart failure associated with advanced congenital heart disease. failed or burned-out transplants, infiltrative and restrictive cardiomyopathies and failed ventricular assist devices. Looking to the future a major unmet need remains in providing total heart support for children and small adults. As such, the present TAH design must be scaled to fit the smaller patient, while providing equivalent, if not superior flow characteristics, shear profiles and overall device thrombogenicity. To aid in the development of a new "pediatric," TAH an engineering methodology known as "Device Thrombogenicity Emulation (DTE)", that we have recently developed and described, is being employed. Recently, to further our engineering understanding of the TAH, as steps towards next generation designs we have: (1) assessed of the degree of platelet reactivity induced by the present clinical 70 cc TAH using a closed loop platelet activity state assay, (2) modeled the motion of the TAH pulsatile mobile diaphragm, and (3) performed fluid-structure interactions and assessment of the flow behavior through inflow and outflow regions of the TAH fitted with modern bi-leaflet heart valves. Developing a range of TAH devices will afford biventricular replacement therapy to a wide range of patients, for both short and long-term therapy.},\r\n project = {TAH},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n The SynCardia() total artificial heart (TAH) is the only FDA-approved TAH in the world. The SynCardia() TAH is a pneumatically driven, pulsatile system capable of flows of >9L/min. The TAH is indicated for use as a bridge to transplantation (BTT) in patients at imminent risk of death from non-reversible bi-ventricular failure. In the Pivotal US approval trial the TAH achieved a BTT rate of >79%. Recently a multi-center, post-market approval study similarly demonstrated a comparable BTT rate. A major milestone was recently achieved for the TAH, with over 1100 TAHs having been implanted to date, with the bulk of implantation occurring at an ever increasing rate in the past few years. The TAH is most commonly utilized to save the lives of patients dying from end-stage bi-ventricular heart failure associated with ischemic or non-ischemic dilated cardiomyopathy. Beyond progressive chronic heart failure, the TAH has demonstrated great efficacy in supporting patients with acute irreversible heart failure associated with massive acute myocardial infarction. In recent years several diverse clinical scenarios have also proven to be well served by the TAH including severe heart failure associated with advanced congenital heart disease. failed or burned-out transplants, infiltrative and restrictive cardiomyopathies and failed ventricular assist devices. Looking to the future a major unmet need remains in providing total heart support for children and small adults. As such, the present TAH design must be scaled to fit the smaller patient, while providing equivalent, if not superior flow characteristics, shear profiles and overall device thrombogenicity. To aid in the development of a new \"pediatric,\" TAH an engineering methodology known as \"Device Thrombogenicity Emulation (DTE)\", that we have recently developed and described, is being employed. Recently, to further our engineering understanding of the TAH, as steps towards next generation designs we have: (1) assessed of the degree of platelet reactivity induced by the present clinical 70 cc TAH using a closed loop platelet activity state assay, (2) modeled the motion of the TAH pulsatile mobile diaphragm, and (3) performed fluid-structure interactions and assessment of the flow behavior through inflow and outflow regions of the TAH fitted with modern bi-leaflet heart valves. Developing a range of TAH devices will afford biventricular replacement therapy to a wide range of patients, for both short and long-term therapy.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);